193 related articles for article (PubMed ID: 38156089)
1. Early intervention and adding effective doses of EGb761 like
Özge A; Ghouri R; Öksüz N; Taşdelen B
Front Neurol; 2023; 14():1240655. PubMed ID: 38156089
[TBL] [Abstract][Full Text] [Related]
2. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
3. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
[TBL] [Abstract][Full Text] [Related]
5. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial.
Youn H; Lee KJ; Kim SG; Cho SJ; Kim WJ; Lee WJ; Hwang JY; Han C; Shin C; Jung HY
Psychiatry Investig; 2021 Mar; 18(3):233-240. PubMed ID: 33685036
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
7. An Overview of Combination Treatment with Citicoline in Dementia.
Gareri P; Veronese N; Cotroneo AM
Rev Recent Clin Trials; 2022; 17(1):4-8. PubMed ID: 34939548
[TBL] [Abstract][Full Text] [Related]
8. Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months.
Öksüz N; Ghouri R; Taşdelen B; Uludüz D; Özge A
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256652
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
10. A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.
Bent-Ennakhil N; Coste F; Xie L; Aigbogun MS; Wang Y; Kariburyo F; Hartry A; Baser O; Neumann P; Fillit H
Neurol Ther; 2017 Jun; 6(1):131-144. PubMed ID: 28508250
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and Network Pharmacology Interaction Analysis of Gingko Biloba (EGB761) Extract with Dual Target Inhibitory Mechanism in Alzheimer's Disease.
Singh M; Jindal D; Kumar R; Pancham P; Haider S; Gupta V; Mani S; R R; Tiwari RK; Chanda S
J Alzheimers Dis; 2023; 93(2):705-726. PubMed ID: 37066913
[TBL] [Abstract][Full Text] [Related]
12. Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study.
Chen S; Price AC; Cardinal RN; Moylett S; Kershenbaum AD; Fitzgerald J; Mueller C; Stewart R; O'Brien JT
PLoS Med; 2022 Dec; 19(12):e1004124. PubMed ID: 36472984
[TBL] [Abstract][Full Text] [Related]
13. Plant-based nutraceutical interventions against cognitive impairment and dementia: meta-analytic evidence of efficacy of a standardized Gingko biloba extract.
Solfrizzi V; Panza F
J Alzheimers Dis; 2015; 43(2):605-11. PubMed ID: 25352453
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2015; 43(2):589-603. PubMed ID: 25114079
[TBL] [Abstract][Full Text] [Related]
15. Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: a cross-sectional survey.
Gopalakrishna G; Brunton S; Pruzin J; Alford S; Hamersky C; Sabharwal A
BMC Psychiatry; 2023 Oct; 23(1):716. PubMed ID: 37794326
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
